<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03169010</url>
  </required_header>
  <id_info>
    <org_study_id>RarePH135</org_study_id>
    <nct_id>NCT03169010</nct_id>
  </id_info>
  <brief_title>Registration Study for Rare Type of Pulmonary Hypertension</brief_title>
  <official_title>Registration Study for Rare Type of Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The knowledge on the rare type of pulmonary hypertension which can not be explained by left
      heart disease, respiratory disease or congenital heart disease is very limited. Investigators
      aim to setup a national registration study for the rare type of pulmonary hypertension, to
      understand the natural history, survival, progression, genetic and environmental
      contributions to disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main research contents of this registration study includes:

        1. Build a baseline database of the rare type of pulmonary hypertension. Collect general
           information, on-set symptoms and time, laboratory examination, imaging results, right
           heart catheterization and treatment information.

        2. Follow up recruited patients at regular intervalsï¼ˆ6m~1y). Collect information on change
           in patients condition, laboratory test and treatment.

        3. Conduct genetic testing for gene mutation related or hereditary pulmonary hypertension.
           Link the clinical database to genetic database.

        4. Establish bio-bank for serum/plasma, urine, stool, tissues or cells.

        5. Establish prognostic study based on the clinical follow-up and genetic database.

        6. Draw diagnostic and treatment algorithm for the rare type of pulmonary hypertension.

      Controls subjects: blood sample and medical data collected once.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Survival Rate of Participants</measure>
    <time_frame>up to 5 years, at 12 months interval</time_frame>
    <description>The percentage of participants who are alive</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genetic alteration in participants with rare type of PH</measure>
    <time_frame>Baseline</time_frame>
    <description>To identify the major genetic alterations in participants with rare type of PH</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Idiopathic Pulmonary Artery Hypertension</arm_group_label>
    <description>Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to idiopathic pulmonary artery hypertension (PAH).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hereditary PAH</arm_group_label>
    <description>Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary PAH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hereditary Hemorrhagic Telangiectasia</arm_group_label>
    <description>Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary hemorrhagic telangiectasia associated PAH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Veno-Occlusive Disease (PVOD)</arm_group_label>
    <description>Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to PVOD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonary Capillary Hemangiomatosis</arm_group_label>
    <description>Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to pulmonary capillary hemangiomatosis associated PAH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavernous Transformation of Portal Vein</arm_group_label>
    <description>Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to cavernous transformation of portal vein associated PAH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTEPH</arm_group_label>
    <description>Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to chronic thromboembolism pulmonary hypertension (CTEPH).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Laboratory results will be analysed to identify disease related biomarkers.</description>
    <arm_group_label>Idiopathic Pulmonary Artery Hypertension</arm_group_label>
    <arm_group_label>Hereditary PAH</arm_group_label>
    <arm_group_label>Hereditary Hemorrhagic Telangiectasia</arm_group_label>
    <arm_group_label>Pulmonary Veno-Occlusive Disease (PVOD)</arm_group_label>
    <arm_group_label>Pulmonary Capillary Hemangiomatosis</arm_group_label>
    <arm_group_label>Cavernous Transformation of Portal Vein</arm_group_label>
    <arm_group_label>CTEPH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic analysis</intervention_name>
    <description>Gene sequencing results will be analysed to identify disease related mutations.</description>
    <arm_group_label>Idiopathic Pulmonary Artery Hypertension</arm_group_label>
    <arm_group_label>Hereditary PAH</arm_group_label>
    <arm_group_label>Hereditary Hemorrhagic Telangiectasia</arm_group_label>
    <arm_group_label>Pulmonary Veno-Occlusive Disease (PVOD)</arm_group_label>
    <arm_group_label>Pulmonary Capillary Hemangiomatosis</arm_group_label>
    <arm_group_label>Cavernous Transformation of Portal Vein</arm_group_label>
    <arm_group_label>CTEPH</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All subjects will have a sample of blood taken for Sanger or whole genome sequencing.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Rare type of pulmonary artery hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant is willing and able to give informed consent for participation in the
             study.

          -  Patients diagnosed as idiopathic pulmonary artery hypertension, hereditary pulmonary
             artery hypertension, hereditary hemorrhagic telangiectasia associated pulmonary artery
             hypertension, pulmonary veno-occlusive disease, pulmonary capillary hemangiomatosis
             associated pulmonary artery hypertension, cavernous transformation of portal vein
             associated pulmonary artery hypertension, special type of congenital heart disease
             associated pulmonary artery hypertension, chronic thromboembolism pulmonary
             hypertension.

          -  All patients should have undergone right heart catheterization, diagnosed according to
             the guideline.

        Exclusion Criteria:

        The participant may not enter the study if ANY of the following apply:

          -  Patients unwilling or unable to provide written consent for participation in the
             study.

          -  Not suffering from the rare type of pulmonary artery hypertension;

        Inclusion criteria-Controls

          -  Participant is willing and able to give informed consent for participation in the
             study.

          -  Self-reported to be healthy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Cheng JING, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xi-Qi XU, MD. PhD.</last_name>
    <phone>+861088322267</phone>
    <email>xuxiqi0928@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xin JIANG, MD. PhD.</last_name>
    <phone>+861088396016</phone>
    <email>jxcs983@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xi-Qi XU, MD. PhD.</last_name>
      <phone>+861088322267</phone>
      <email>xuxiqi0928@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xin JIANG, MD. PhD.</last_name>
      <phone>+861088396016</phone>
      <email>jxcs983@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>GaliÃ¨ N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, Klepetko W, McGoon MD, McLaughlin VV, Preston IR, Rubin LJ, Sandoval J, Seeger W, Keogh A. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D60-72. doi: 10.1016/j.jacc.2013.10.031. Review.</citation>
    <PMID>24355643</PMID>
  </reference>
  <reference>
    <citation>Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-54. doi: 10.1016/j.jacc.2009.04.012. Review.</citation>
    <PMID>19555858</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>China National Center for Cardiovascular Diseases</investigator_affiliation>
    <investigator_full_name>Zhi-Cheng JING, MD</investigator_full_name>
    <investigator_title>Director of Thrombosis and Hemostasis Center of Chinese Academy of Medical Sciences Fuwai Hospital</investigator_title>
  </responsible_party>
  <keyword>registry</keyword>
  <keyword>pulmonary hypertension</keyword>
  <keyword>survival</keyword>
  <keyword>biomarker</keyword>
  <keyword>whole genome sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Consent for sharing of non identifiable study data for regulatory authorities.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

